Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC chemo holiday + lenvatinib + toripalimab in unresectable biliary tract cancers
ChiCTR2300067514Phase 3Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jan 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gemcitabine, cisplatin, lenvatinib and toripalimab in biliary cancer and cholangiocarcinoma (CCA), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Objective response rate. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
gemcitabinecisplatinlenvatinibtoripalimab
03
Conditions
biliary cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2300067514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067514.